Kibum Kim
Assistant Professor, Department of Pharmacy Systems, Outcomes and Policy,
Director of Graduate Studies, Department of Pharmacy Systems, Outcomes and Policy
Contact
Address:
833 S WOOD STREET, CHICAGO, ILLINOIS
Office Phone:
Email:
Related Sites:
About
Overview:
Kibum Kim is an Assistant Professor of Pharmacy Systems, Outcomes, and Policy. He graduated from the University of Illinois at Chicago with his PhD in Pharmacy, with his specialty in pharmacoeconomics and health outcomes research. Prior to working at the University of Illinois at Chicago, he was a research assistant professor of the University of Utah and served as an investigator for comparative effectiveness and market access projects. He also interned at Abbvie, Inc., Takeda Pharmaceuticals, and eMax Health company where he assisted multiple market access and real-world outcome projects. Dr. Kim’s research interest includes contemporary trends in medication utilization, causal inference in health outcome assessment, and model-based cost-effectiveness analysis.
During his career, Dr. Kim has published his research in clinical and economic outcomes of treatment options for diabetes, cardiovascular disorders, and oncology. His recent study activities focus on health technology assessment, clinical utility of diagnostic testing, precision medicine, and the role of bioinformatics in improving healthcare outcomes.
Research Interests:
• Utility of precision medicine and molecular diagnostic testing
• Utilization and outcomes of antiplatelet therapy and anti-coagulation management
• Glycemic control associated with anti-diabetic agent use and concurrent medication to prevent patient from long-term complications
• Resource utilization and healthcare cost across multiple chronic conditions
• Research methods in health outcomes research using real-world databases
• Bioinformatics in health outcomes research
Teaching and Supervision
Ph.D. Thesis Research (PSOP 599), 8/25/2025 – 12/5/2025
Independent Study (PSOP 596), 8/25/2025 – 12/5/2025
Econmc Eval of Hlthcr Interven (PSOP 573), 8/25/2025 – 12/5/2025
Pharmacoeconomics and Payment (PHAR 565), 8/25/2025 – 12/5/2025
Pharmacoeconomics and Payment (PHAR 565), 8/25/2025 – 12/5/2025
Independent Study (PSOP 596), 6/16/2025 – 8/8/2025
PSOP Project (PSOP 597), 1/13/2025 – 5/2/2025
Independent Study (PSOP 596), 1/13/2025 – 5/2/2025
Pharmacoeconomics and Payment (PHAR 565), 8/26/2024 – 12/6/2024
Selected Grants
Kaward - Accumulation of Elevated Risk Associated with Treatment-Escalation Disparity in patients with Type 2 Diabetes (ACCELERATED-T2D) � Resubmission, National Institutes of Health (National Institute of Diabetes and Digestive and Kidney Diseases)., 9/15/2025 - 8/31/2030, Obligated Amount: $147747; Anticipated Amount: $738735
Economic outcomes of first-line ANG2 vs. CVP in patients with KT for perioperative hemodynamic maintenance., La Jolla Pharmaceutical Company., 6/30/2023 - Present, Obligated Amount: $120000; No Anticipated Amount Set
Type 2 Diabetes Treatment Pathways by Socioeconomic Indicators from Electronic Healthcare Records and Geospatial Analytics, Vahlteich Research Award., 2/15/2023 - 11/18/2022, Obligated Amount: $50000; No Anticipated Amount Set
Exploratory Investigation in the Ubiquity and Outcomes of Non-Medical Medication Switching in Aged Population with Acute Coronary Synderome or Atrial Fibrillation, National Institute on Aging., 5/12/2022 - Present, Obligated Amount: $24; Anticipated Amount: $275000
2022 - 2023 Institute for Clinical and Economic Review Consulting Agreement, Institute for Clinical and Economic Review., 1/1/2022 - 12/31/2026, Obligated Amount: $610000; Anticipated Amount: $610000
Cost-Effectiveness and Budget Impact of Artificial Intelligence-driven Risk-Stratification in Patients with Diabetic Kidney Disease (DKD), University of Utah., 10/1/2021 - 6/30/2023, Obligated Amount: $247482; Anticipated Amount: $247482
Leveraging machine learning to enhance electronic health record data for drug effectiveness and safety research in depression, .., 6/1/2021 - 5/31/2023, Obligated Amount: $165000; Anticipated Amount: $165000
Preliminary assessment of the alteration of oral antiplatelet agent regimens in patients with acute coronary syndrome, Greater Plains Collaborative., 11/1/2019 - 2/22/2021, Obligated Amount: $10000; Anticipated Amount: $10000
Selected Publications
Kim, Kibum, Keur, Jasmeen, Anderson, Halie, Radwański, Przemysław B, Munger, Mark A. (2025). Ivabradine and Atrial Fibrillation Incidence A Nested Matching Study. JACC Advances, 4, (12), 102282. doi:10.1016/j.jacadv.2025.102282.
Joshi, Mrinmayee, Pickard, A Simon, Kim, Kibum, Sharp, Lisa K, Gerber, Ben S, Touchette, Daniel R. (2025). Health-related quality of life in racial and ethnic minority adults with type 2 diabetes: validity and responsiveness of the EQ-5D-3L. Quality of Life Research, 34, (11), 3147-3158. doi:10.1007/s11136-025-04070-2.
Perez, B, Kim, K, Munger, M, Radwanski, P. (2025). 1376 Does Spironolactone Reduce Atrial Fibrillation from Cardiac Surgery? An Observational Cohort Study. Journal of the American Pharmacists Association, 65, (5), 102830. doi:10.1016/j.japh.2025.102830.
Sarker, Jyotirmoy, Kim, Michael, Patton, Samantha, Radwański, Przemysław B, Munger, Mark A, Kim, Kibum. (2025). Comparative Risk of Atrial Fibrillation Onset in Statin‐Treated Patients Initiating Icosapent Ethyl and Omega‐3 Acid Ethyl Esters: A Retrospective Cohort Study. Journal of the American Heart Association, 14, (15), e038846. doi:10.1161/jaha.124.038846.
De Los Santos, Bertha, Kim, Kibum. (2025). EE118 Trends in Antidiabetic Medication Use and Outpatient Pharmacy Costs in a Commercially Insured Diabetes Population from a US Payer Perspective. Value in Health, 28, (6), s83. doi:10.1016/j.jval.2025.04.410.
Joshi, Mrinmayee, Kim, Kibum, Pickard, A Simon, Sharp, Lisa, Gerber, Ben S, Touchette, Daniel. (2025). EE496 Long-Term Cost-Effectiveness of a Mobile Health Intervention Delivered by Clinical Pharmacists and Community Health Workers for Type 2 Diabetes Management. Value in Health, 28, (6), s153. doi:10.1016/j.jval.2025.04.2092.
Joshi, Mrinmayee, Kim, Kibum, Pickard, A Simon, Sharp, Lisa K, Gerber, Ben S, Touchette, Daniel R. (2025). Mobile health intervention for type 2 diabetes management delivered by community health workers and clinical pharmacists: Intervention costs and healthcare resource utilization. American Journal of Health-System Pharmacy, zxaf153. doi:10.1093/ajhp/zxaf153.
Anderson, Heather D, Kim, Kibum, Zhang, Mingyuan, Gutierrez, Eric, Malhotra, Jodie, Tak, Casey. (2025). Assessing Availability of Depression Severity Indicators in Electronic Health Record Data: A Retrospective Study in Two Large Academic Health Care Systems in the United States. Psychological Services. doi:10.1037/ser0000969.
Choi, Sun A, Touchette, Daniel R, Kim, Kibum. (2025). Health care costs and resource utilization among patients with myasthenia gravis in the United States.. Journal of Managed Care & Specialty Pharmacy, 31, (5), 472-481. doi:10.18553/jmcp.2025.31.5.472.
Education
Degrees:
PhD, University of Illinois at Chicago, United States, 2017
MSc, Catholic University of Daegu, Korea, Republic of, 2008
BPharm, Catholic University of Daegu, Korea, Republic of, 2006
Postgraduate Training:
Research Fellow, University of Utah, United States, 2018
Selected Presentations
Kim, Kibum, Ollendorf, Daniel, Wasfy, Jason. (2025 September 25). Brensocatib for Non-Cystic Fibrosis Bronchiectasis: Effectiveness and Value. ICER Public Meeting. Zoom On-Line.